Terushige Iike

Mr. Terushige Iike, M.B.A., is CEO of H3, a position he has held since 2018. Mr. like brings over three decades of pharmaceutical experience to H3 as he leads all facets of the company’s business strategy. In addition to his role at H3, Mr. Iike is President of the Oncology Business Group at Eisai Co., Ltd., overseeing the international end-to-end activities and business development of Eisai’s global oncology efforts. In his career at Eisai, Mr. Iike has assumed various roles of increasing responsibility in both R&D and corporate strategy, including positions of Vice President of Corporate Strategy and President of the Japan/Asia Clinical Research of Eisai Product Creation Systems. In 2014, he was named Chief Product Creation Officer, responsible for Eisai’s global research and drug development program. He was then named a Senior Vice President of Eisai in 2015 and was elected to his current position of President of the Oncology Business Group in 2016.

Mr. like earned his M.B.A. from Harvard Business School and his B.S. in pharmaceutical sciences from the University of Tokyo.

Seeking Additional Information?

Contact